Arcturus Therapeutics Holdings Inc.

ARCT

US03969T1097

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
26.17 ^USD	-3.00%		-0.57%	-17.00%

Mar. 27	Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	MT
Mar. 21	Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	MT

Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) added to Russell 2500 Growth Index

June 24, 2022 at 12:00 am EDT

Latest news about Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	Mar. 27	MT
Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	Mar. 21	MT
Transcript : Arcturus Therapeutics Holdings Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM	Mar. 14
Canaccord Genuity Adjusts Arcturus Therapeutics Holdings' PT to $87 From $81, Maintains Buy Rating	Mar. 11	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating	Mar. 08	MT
Transcript : Arcturus Therapeutics Holdings Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops	Mar. 07	MT
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q4 Revenue $34M, vs. Street Est of $37.9M	Mar. 07	MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 07	CI
Arcturus Therapeutics Holdings Inc. Announces Executive Changes	Feb. 23	CI
Arcturus Gets European Orphan Medicinal Product Label For ARCT-032 to Treat Cystic Fibrosis	Feb. 22	MT
Citigroup Raises Price Target on Arcturus Therapeutics to $48 From $40, Maintains Buy Rating	Feb. 08	MT
Transcript : Arcturus Therapeutics Holdings Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:00 PM	Jan. 09
Passport Technologies, Inc. Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA Delivery Systems	Jan. 05	CI
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster	Dec. 21	CI
Canaccord Genuity Initiates Arcturus Therapeutics With Buy Rating, $81 Price Target	Dec. 13	MT
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults	Nov. 28	CI
Sector Update: Health Care Stocks Softer Monday Afternoon	Nov. 27	MT
Arcturus Therapeutics Says FDA Grants Orphan Drug Designation for ARCT-032 to Treat Cystic Fibrosis	Nov. 27	MT
Arcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic Fibrosis	Nov. 27	DJ
Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo	Nov. 27	RE
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	Nov. 15	MT
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges; Shares Soar Premarket	Nov. 15	MT
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges	Nov. 14	MT
Transcript : Arcturus Therapeutics Holdings Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14

Chart Arcturus Therapeutics Holdings Inc.

Duration

Period

Chart Arcturus Therapeutics Holdings Inc.

More charts

Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Arcturus Therapeutics Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.98 USD

Average target price

67.89 USD

Spread / Average Target

+151.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARCTURUS THERAPEUTICS HOLDINGS INC.	-17.00%	726M
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research